©2022 Stanford Medicine
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Not Recruiting
Trial ID: NCT01806675,7,8,9,18,20,22,30,45,62,80,45550
Purpose
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer
patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study
participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell
carcinoma (RCC) who are receiving antiangiogenesis treatment.
Official Title
Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis
Stanford Investigator(s)
Heather Wakelee
Professor of Medicine (Oncology)
Lawrence Recht, MD
Professor of Neurology and, by courtesy, of Neurosurgery
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Melinda L. Telli, M.D.
Associate Professor of Medicine (Oncology)
Eligibility
Inclusion Criteria:
- Provides written informed consent
- Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and
neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis
treatment or treatment with other drugs that may alter angiogenesis
- Able to remain still for duration of each imaging procedure (about one hour)
Exclusion Criteria:
- Pregnant or nursing
- Contraindication to MRI
- History of renal insufficiency (only for MRI contrast administration)
Intervention(s):
drug: 18F-fludeoxyglucose (18F-FDG)
drug: 18F-FPPRGD2
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061